Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22062479 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL1205232 | 0.84 | LNPEP (0.57) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL20266373 | 0.83 | PTGER4 (0.64) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL763198 | 0.82 | LNPEP (0.62) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL2014323 | 0.81 | LNPEP (0.56) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL23703820 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL16301235 | 0.81 | PTGER4 (0.65) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL24265280 | 0.80 | HDAC1 (0.53) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL23287055 | 0.80 | LNPEP (0.53) | KDM4EALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL22009835 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPTPTGER4LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4219487-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3806955-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3806955-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219487-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3806955-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020234726-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020234726-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | KDM4E 899/4885ALDH1A1 743/4885MAPT 3530/4885 |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | KDM4E 1142/4885ALDH1A1 907/4885MAPT 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.